FHTX · Foghorn Therapeutics Inc. · Executive Compensation

$4.67 -0.16 (-3.31%) At close · Sep 9

Russell 2000 member Rebalance outlook locked

Market Cap

$286.83M

59.39M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Adrian Gottschalk	President and Chief Executive Officer	$638,000	—	—	$1,334,037	$385,990	$3,000	$2,361,027
Steven Bellon	Chief Science Officer	$505,000	—	—	$469,255	$222,200	$3,000	$1,199,455
Alfonso Quintás-Cardama	Chief Medical Officer	$494,000	—	—	$419,605	$217,360	$3,000	$1,133,965

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Kristian Humer	Chief Financial Officer	$336,458	$87,000	—	$1,250,797	$161,500	$52,848	$1,888,603
Adrian Gottschalk	President and Chief Executive Officer	$601,500	—	—	$673,861	$281,201	$3,000	$1,559,562
Anna Rivkin	Chief Business Officer	$143,333	$135,000	—	$1,123,912	$48,733	$21,606	$1,472,584
Steven Bellon	Chief Science Officer	$485,000	—	—	$249,312	$164,900	$3,000	$902,212
Alfonso Quintás-Cardama	Chief Medical Officer	$471,000	—	—	$135,349	$160,140	$3,000	$769,489

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Adrian Gottschalk	President and Chief Executive Officer	$579,000	—	—	$1,719,292	$202,650	$3,000	$2,503,942
Alfonso Quintás-Cardama	Chief Medical Officer	$144,432	$110,000	—	$1,544,374	$43,400	$2,329	$1,844,535
Steven Bellon	Ph.D.. Chief Scientific Officer	$445,000	—	—	$614,894	$124,600	$3,000	$1,187,494

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Adrian Gottschalk	President and Chief Executive Officer	$575,000	—	—	$4,645,819	$215,625	—	$5,436,444
Steven Bellon	Ph.D.. Chief Scientific Officer	$435,000	—	—	$1,580,167	$130,500	—	$2,145,667
Michael LaCascia	Chief Legal Officer	$435,000	—	—	$1,422,677	$130,500	—	$1,988,177
Allan Reine	Chief Financial Officer	$435,000	—	—	$1,421,769	$130,500	—	$1,987,269
Alfonso Quintás-Cardama	Chief Medical Officer	—	—	—	—	—	—	—

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Adrian Gottschalk	President and Chief Executive Officer	$540,000	—	—	$3,370,482	$405,000	—	$4,315,482
Allan Reine	Chief Financial Officer	$416,000	—	—	$1,348,746	$249,600	—	$2,014,346
Samuel Agresta	Chief Medical Officer	$428,500	—	—	$1,124,004	$257,100	—	$1,809,604
Carl P. Decicco	Former Chief Scientific Officer	$428,500	—	—	$1,124,004	$257,100	—	$1,809,604

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Adrian Gottschalk	President and Chief Executive Officer	$478,950	—	—	$1,834,007	$311,318	—	$2,624,275
Michael LaCascia	Chief Legal Officer	$59,423	$60,000	—	$1,869,416	—	—	$1,988,838
Carl P. Decicco	Former Chief Scientific Officer	$412,000	—	—	$542,224	$214,240	$50,000	$1,218,464
Samuel Agresta	Chief Medical Officer	$412,000	—	—	$542,224	$99,573	—	$1,053,797

Fiscal 2019

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Carl P. Decicco	Chief Scientific Officer	$400,000	—	—	$1,474,337	$136,000	$60,000	$2,070,337
Adrian Gottschalk	President and Chief Executive Officer	$465,000	—	—	$642,918	$197,625	—	$1,305,543
Samuel Agresta	Chief Medical Officer	$116,667	$300,000	—	$785,607	—	—	$1,202,274

Executive changes

Person	Role	Change	Effective	Filed
Ryan D. Maynard	Chief Financial Officer	Appointed	2026-02-23	2026-02-23
Jeff Sacher	Treasurer	Appointed	2025-12-03	2025-12-04
Jeff Sacher	interim Chief Financial Officer	Appointed	2025-12-03	2025-12-04
Kristian Humer	Chief Financial Officer	Resigned	2025-11-14	2025-11-05
Neil J. Gallagher, M.D., Ph.D.	Class II director	Appointed	2025-05-01	2025-05-01
Stuart Duty	Class II director	Appointed	2025-05-01	2025-05-01
Adam M. Koppel, M.D., Ph.D.	member of the board of directors	Resigned	2024-12-29	2024-12-30

Key facts CIK 1822462 CUSIP 344174107 13F (30d) 65 filings 65 filers Visit website Investor relations